Live feed09:31:00·43dPRReleasevia QuantisnowFirst Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026ByQuantisnow·Wall Street's wire, on your screen.GERN· Geron CorporationHealth Care
